Brief: Baudax Bio Posts Qtrly Loss Per Share $1.51
16/08/2023 13:13
Aug 16 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
AND
PROVIDES BUSINESS UPDATE
* BAUDAX BIO INC - COMPANY TO PRIORITIZE DEVELOPMENT OF NEW
TI-168
TREG ASSET FOR HEMOPHILIA A
* BAUDAX BIO INC - QTRLY LOSS PER SHARE $1.51
Source text for Eikon: ID:nGNXccmRL1
Further company coverage: BXRX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer